Compare Kohl's Corporation (KSS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Kohl's Corporation trades at $21.11 (market cap $2.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.37% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KSS | TVTX | |
|---|---|---|
Market Cap | $2.39B | $4.88B |
Volume | 4,591,325 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $67.52 |
52-Week Low | $11.72 | $26.79 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.99B | $5.01B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $21.10, down 0.33% on the day, with a bullish technical signal from moving averages and a low valuation profile (P/E 9.06, P/S 0.16). Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a raised full-year outlook, highlight improving operational momentum, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. The company maintains a dividend, with the next payment of $0.13 scheduled for September 23, 2026.
The stock presents a value opportunity with attractive multiples and positive earnings surprises, but faces headwinds from 18 consecutive quarters of sales declines and competitive pressures. Analyst sentiment is mixed with a 30% buy rating, and the consensus price target of $15.50 implies downside risk from current levels. Execution on holiday sales and margin stabilization are critical for sustaining the recent rebound.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
